Despite delay, MannKind expects quick approval

Despite the FDA's announcement that it would miss the January 16 deadline for its ruling on MannKind's inhaled insulin drug Afrezza, CEO Alfred Mann is still confident that an approval will arrive in short order. The agency says it needs more time to complete its inspection of an insulin manufacturing facilities. "My guess is an action letter will come within days of the inspection," Mann said at the J.P. Morgan healthcare conference, as reported in Reuters. "We have nothing from our side that's due." Article

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.